DENVER —The largest global, prospective, noninterventional study of faricimab demonstrated “robust, rapid” anatomical improvements in patients with diabetic macular edema, according to a speaker.
The VOYAGER study included real-world data from more than 5,000 patients from 28 countries who were treated with Vabysmo (faricimab, Genentech/Roche) for DME, wet age-related macular degeneration or retinal vein occlusion. Robert P. Finger, MD, PhD, of University of Heidelberg, and colleagues performed a volumetric analysis of intraretinal fluid, subretinal fluid and central subfield thickness over 6